DPD. I. Paveliev

D. I. Paveliev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


D. I. Paveliev has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of approaches of the World Health Assembly to the retention or destruction of variola virus stocks

    by Gennady G. Onishchenko, Онищенко Геннадий Григорьевич, Lyudmila F. Stovba, Стовба Людмила Федоровна, Oleg V. Chukhralya, Чухраля Олег Васильевич, Dmitry I. Paveliev, Павельев Дмитрий Игоревич, Sergey V. Savenko, Савенко Сергей Вадимович, et al.

    After smallpox eradication was certified in 1980, the international community faced the question of the fate of the remaining collections of Variola virus (VARV). Debate over their destruction has continued for more than four decades. Objective. To conduct a historical-chronological analysis of World Health Organization (WHO) and World Health Assembly (WHA) documents in order to trace changes in the arguments and approaches concerning the retention and possible destruction of VARV stocks. Resolutions of the World Health Assembly, WHO documents, and materials from the WHO Advisory Committee on Variola Virus Research were analyzed as sources; historical-chronological and comparative methods were employed. After storage was centralized in two WHO collaborating centers, the proposed timelines for destruction were repeatedly reconsidered. In 1999, the WHA authorized temporary retention to allow further international research; in 2002, retention was continued subject to results-oriented and time-limited studies. During the 2010s, risks associated with advances in synthetic biology became more prominent in the discussion. In 2019, the WHA extended the research programme for a further five years. Conclusion. The history of this issue reflects not a linear progression toward a final decision to destroy the VARV, but rather a periodic review of retention timelines and research conditions. The WHO Advisory Committee plays a pivotal scientific advisory role in evaluating the necessity, direction, and outcomes of VARV research, and its expert findings inform deliberations regarding the future of the stocks. The current WHO approach is characterized by a combination of rigorous research oversight, biosafety requirements, and periodic reviews of the research program.

  • Two-component vector-based vaccine Ad26.ZEBOV, MVA-BN-Filo against Ebola fever: A review of clinical studies

    by L. F. Stovba, O. V. Chukhralya, D. I. Paveliev, M. I. Soldatenkova, D. P. Belozerov, A. A. Petrov, S. V. Borisevich

    INTRODUCTION. High reactogenicity of the existing Ebola vaccines necessitates the development of safer and more efficacious alternatives. A solution is to use new recombinant vectorbased vaccines, such as Ad26.ZEBOV (a recombinant vaccine based on non-replicating human Ad26 serotype with an inserted glycoprotein gene of Zaire ebolavirus strain) and MVA-BN-Filo (a recombinant vaccine based on modified vaccinia Ankara strain), currently undergoing clinical trials to confirm their efficacy and safety. AIM. This study aimed to systematize clinical trial data in order to assess efficacy, safety, and immunogenicity of the two-component recombinant Ad26.ZEBOV, MVA-BN-Filo vaccine used to prevent Ebola hemorrhagic fever in various population groups. DISCUSSION. Literary sources were analyzed in the PubMed, ScienceDirect, and eLIBRARY.RU databases over the period of 2009–2024. Phase I–III clinical trials confirmed that the twocomponent Ebola vaccination regimen (Ad26.ZEBOV, MVA-BN-Filo) provides a strong and sustained immune response. Seroconversion reached 87–95% three weeks after the first administration and up to 100% after revaccination, with immunity lasting for at least a year. Adverse events (local and systemic, mild to moderate severity) were observed in half of the participants; serious adverse events were not associated with vaccination and occurred in less than 1%. In pregnant women, the vaccination did not increase the risk of adverse outcomes while ensuring the transmission of antibodies to the fetuses. In children and adolescents, seroconversion exceeded 90%; revaccination significantly enhanced the immune response. In HIV-infected individuals, seroconversion reached 80–85%, which is comparable to the general population. Malaria or helminthiasis did not reduce the immunization effectiveness. Considering the above, the World Health Organization and the European Medicines Agency approved this vaccination schedule in 2020 in adults and children over one year of age, including those with concomitant infections. CONCLUSIONS. The two-component Ad26.ZEBOV, MVA-BN-Filo vaccine shows high immunogenicity and a good safety profile. The primary and booster vaccination schedule is effective in adults, children over one year of age, pregnant women, and individuals with concurrent infections, including HIV, malaria, and helminthiasis. The vaccine reduces the risk of Ebola transmission and can be used for a mass immunization strategy in endemic regions and during the disease outbreaks.

  • Open Access

    Smallpox Vaccine LC16m8: Production, Properties, and Prospects

    by L. F. Stovba, O. V. Chukhralya, A. A. Petrov, S. A. Mel’nIkov, D. I. Pavel’eV, S. V. Borisevich

    Abrogation of obligatory vaccination against smallpox has lead to degradation of herd immunity and humanity has become vulnerable to long known infections, such as monkeypox (mpox), cowpox, camelpox, buffalopox and emerging ones, caused by viruses Alaska and Akhmeta. This situation demands availability of safe smallpox vaccines, the immunogenicity of which is comparable to vaccines used in the period of smallpox elimination. The aim of this review is to analyze the research of Japanese scientists on the production and investigation of properties of the smallpox vaccine LC16m8 and to assess further prospects for the use of the LC16m8 strain. The LC16m8 vaccine was obtained based on one of the Lister clones and has been licensed in Japan since 1975. Whole-genome sequencing revealed that its main difference from the genome of the original strain is a mutation in the B5R gene, which determines its safety for laboratory animals and humans. The immunogenicity of the vaccine based on this strain is comparable to the immunogenicity of the first generation vaccines: Lister, Dryvax, Ikeda. According to WHO recommendations, second generation vaccines ACAM 2000 and third generation vaccines based on the LC16m8 strain are reserve drugs. However, the established fact that the LC16m8 strain, when passaged in cell culture, spontaneously reverts to the original variant of the Lister strain led to genetic engineering work to delete the B5R gene to obtain the LC16m8Δ mutant, which is not capable of reversion. A vaccine based on the LC16m8Δ strain could technically be classified as a fourth generation drug, and taking into account the high immunogenicity and relative safety of this strain based on the results of preclinical studies, there is a real prospect of producing an advanced and effective reserve drug based on it. Thus, analysis of long-term data on the study of the LC16m8 vaccine indicates that this drug is superior to other analogues of the 1st, 2nd and 3rd generation in terms of effectiveness and safety. Further genetic engineering work with this strain, which made it possible to obtain a safe but immunogenic genovariant of the LC16m8Δ strain, is a clear example of a productive movement towards the development of safe and effective fourth generation vaccines.


  • Open Access

    Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain

    by L. F. Stovba, O. V. Chukhralya, D. I. Pavel’eV, N. K. Chernikova, S. V. Borisevich

    The aim of this review was to investigate the use of the vaccines based on vaccinia virus, MVA stain, and adenovirus vectors for the prevention of Ebola virus disease. The recombinant MVA strains expressing antigen determinants of Filoviridae family representatives were assessed as possible candidates for vaccine preparations. Application of this virus as a vaccine vector is conditioned by the absence of herd immunity to smallpox and its safety for healthy adult volunteers, children, adolescents, individuals suffering from tuberculosis, persons aged 56–80 years, people with diagnosed atopic dermatitis, AIDS. Furthermore, immunization with the vaccine on the basis of vaccinia virus, MVA strain, does not cause complications associated with cardiovascular diseases. Preclinical trials on immunogenicity and protective efficiency were carried out on immune-competent and immune-compromised mice; guinea pigs adapted to Ebola virus; rhesus macaques and cynomolgus monkeys. Presented are the results of experiments on the creation of vaccines expressing either only viral glycoprotein or viral glycoprotein and structural protein Vp40. Given that Ebola fever and other filovirus infection outbreaks are hard to predict, multivalent vaccines that would be able to provide protection against all filovirus species were designed. Clinical trials on simultaneous use of the vaccines based on recombinant adenovirus vectors and MVA strain showed more pronounced safety of vaccines on the basis of recombinant MVA strain. Studies of humoral and T-cell immune responses have revealed that this vector is more suitable for booster vaccination in case of heterologous prime/booster immunization scheme. Vaccination regimens for forming strong durable immune responses have been analyzed. Epidemiological modeling provided evidence that preventive immunization leading to long-term immunity in healthy population in areas of high epidemic risk will be of greater benefit in terms of controlling future outbreaks compared to ring immunization that was effective during smallpox eradication campaign. Increased immunity level, induced by prime/booster vaccination, persisting for a long period of time, will have an advantage over accelerated ring immunization; when the duration of protection is more significant than the speed it is formed at.


  • Open Access

    Development of a reagent kit for the detection of SARS-CoV-2 virus RNA using real-time reverse transcription polymerase chain reaction

    by A.V. Kazantsev, Ya.I. Alekseev, O.V. Chuhralya, D.A. Varlamov, N.V. Karulina, T.E. Sizikova, D.I. Pavel'Ev, A.A. Petrov, A.V. Manoshkin, A.V. Kuzubov, et al.

    Разработка набора реагентов для выявления РНК вируса SARS-CoV-2 методом обратной транскрипции полимеразной цепной реакции в реальном времени

  • Open Access

    Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections

    by L. F. Stovba, V. T. Krotkov, С. А. Мельников, D. I. Paveliev, N. K. Chernikova, S. V. Borisevich

    Epidemic vector-borne viral infections pose a serious threat to public health worldwide. There is currently no specific preventive treatment for most of them. One of the promising solutions for combating viral fevers is development of vector vaccines, including MVA-based vaccines, which have virtually no adverse side effects. The safety of the MVA strain and absent reactogenicity of recombinant MVA vaccines have been supported by many clinical trials.The article focuses on test results for similar preventive products against viral fevers: Crimean-Congo hemorrhagic fever, Rift Valley fever, yellow fever, Chikungunya and Zika fevers.Their immunogenicity was evaluated on immunocompetent and immunocompromised white mice; their protective efficacy was assessed on immunocompromised white mice deficient in IFN-α/β receptors, that are used for experimental modeling of the infection. Nearly all the new recombinant vaccines expressing immunodominant antigens demonstrated 100% protective efficacy. It has been found that although the vaccine expressing Zika virus structural proteins induced antibodies against specific viral glycoproteins, it can be associated with high risks when used for prevention of Zika fever in individuals who had dengue fever in the past, due to the phenomenon known as antibody-dependent enhancement of infection, which can occur in diseases caused by antigenically related flaviruses. For this reason, the vaccine expressing non-structural protein 1 (NS1) was developed for vaccination against Zika fever.The yellow fever vaccine developed on the MVA platform had immunogenicity similar to that of the commercial 17D vaccine, outperforming the latter in safety.

  • Analysis of main and small populations of lymphocytes of rhesus macaque peripheral blood using the method of flow cytometry

    by 48 Central Scientifi c Research Institute of the Ministry of Defense of the Russian Federation, G.V. Borisevich, S.L. Kirillova, A.N. Petrov, V.N. Lebedev, Y.I. Pashchenko, V.B. Kirillov, T.E. Sizikova, D.I. Pavel'EV, V.B. Pantyukhov, et al.